Change search
ReferencesLink to record
Permanent link

Direct link
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Neurology.
Show others and affiliations
2011 (English)In: Annals of Neurology, ISSN 0364-5134, E-ISSN 1531-8249, Vol. 69, no 1, 83-89 p.Article in journal (Refereed) Published
Abstract [en]

Our data demonstrate that natalizumab treatment reduces the accumulation of nerve injury in relapsing forms of MS. It is anticipated that highly effective anti-inflammatory treatment can reduce axonal loss, thereby preventing development of permanent neurological disability.

Place, publisher, year, edition, pages
2011. Vol. 69, no 1, 83-89 p.
Keyword [en]
fibrillary acidic protein; placebo-controlled trial; cerebrospinal-fluid; neurofilament light; disease-activity; lesion load; disability; MS; CSF
National Category
URN: urn:nbn:se:umu:diva-42424DOI: 10.1002/ana.22247PubMedID: 21280078OAI: diva2:409221
Available from: 2011-04-07 Created: 2011-04-07 Last updated: 2011-09-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sundström, PeterSvenningsson, Anders
By organisation
In the same journal
Annals of Neurology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 46 hits
ReferencesLink to record
Permanent link

Direct link